Phase 3
Completed N=38
The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Neonatal Abstinence Syndrome · Aromatherapy
Source: ClinicalTrials.gov NCT03097484 ↗
Enrolled (actual)
38
Serious AEs
0.0%
Results posted
May 2019
Primary outcomePrimary: Length of Hospitalization — 17.8; 11.4 days — p=0.03
◆ Published Evidence
Highly cited
221citations · ~18 / year
Kangaroo mother care to reduce morbidity and mortality in low birthweight infants.
Summary
Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome
Linked Publications (5)
-
Kangaroo mother care to reduce morbidity and mortality in low birthweight infants.
-
Lavender fragrance cleansing gel effects on relaxation.
-
A randomized placebo-controlled trial of massage therapy on the immune system of preterm infants.
-
Lavender bath oil reduces stress and crying and enhances sleep in very young infants.
-
Influence of prone positioning on premature newborn infant stress assessed by means of salivary cortisol measurement: pilot study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Length of Hospitalization |
17.8; 11.4 | 0.03 sig |
| SECONDARY Length of Medication Therapy |
12.7; 7.4 | 0.05 |
Eligibility Criteria
Inclusion Criteria
- Infants greater than or equal to 36 weeks EGA
- Intrauterine opioid exposure
- Primary diagnosis of NAS
- Parental permission to participate
Exclusion Criteria
- Infants less than 36 weeks EGA
- Major congenital anomalies
- Latrogenic drug withdrawal
- Diagnosis of infection or respiratory distress
- Prior initiation of opioid replacement therapy
- Non-English speaking
- Infants with respiratory conditions
Data sourced from ClinicalTrials.gov (NCT03097484) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.